



**RECADEMY™**

# What's Working in OUD Treatment & System Transformation: The ROI of MOUD in Health Systems, Payers & Communities

March 19, 2026

# Why This Topic Matters

## Health Systems & Payers Often Ask:



Where do MOUDs improve outcomes?



Which patient populations benefit most?



How do these treatments affect engagement and retention?



Do they reduce emergency department visits and total cost of care?

# Emerging Real-World Evidence Shows These Treatments Can:

-  Improve retention in treatment
-  Strengthen transitions of care
-  Reduce overdose risk
-  Lower total cost of care despite higher medication costs

# Today's Speakers



**Charles C. Whitehill, MD**  
Chief of Addiction Medicine  
& Recovery Services (AMRS)  
Napa Solano Kaiser



**Stuart Buttlair, PhD**  
Vice President of Clinical  
Excellence & Leadership  
*OPEN MINDS*

# Fireside Discussion


*A conversation on how MOUDs for opioid use disorder can improve engagement, retention, and transitions of care while creating clinical and financial value for health systems, payers, and communities.*

# Framing Value & ROI



When health systems or payers evaluate long-acting injectable medications for OUD, what do you think they often get wrong at the outset? What metrics actually matter most?

# Framing Value & ROI



How should organizations think differently about value when they move from daily or sublingual formulations to long-acting injectables?

# Where MOUD Strengthens the Cascade of Care




Across the OUD cascade—initiation, stabilization, retention, and transitions—where have you seen LAI MOUD make the most meaningful difference?

# Where MOUD Strengthens the Cascade of Care



Are there specific patient profiles or care settings where the return on investment is especially strong?

# Engagement, Adherence & Retention



From a practical standpoint, how does LAI MOUD change engagement and retention patterns in the first 90 days and over the first year of treatment?

# Engagement, Adherence & Retention



What have you observed in terms of missed visits, medication gaps, and treatment continuity compared to daily dosing models?

# High-Risk Populations & Transitions




Transitions of care remain one of the most fragile points in OUD treatment. How does LAI MOUD function differently during ED discharges, hospital transitions, or release from incarceration?

# High-Risk Populations & Transitions



Since so many people in psychiatric inpatient care settings have comorbid substance use disorders, what role do you actually see in reducing overdose risk during those vulnerable windows?

# Operational & Financial Considerations



What operational barriers most commonly slow adoption, even when leadership is supportive?

# Operational & Financial Considerations




How have organizations successfully aligned clinical teams, pharmacy, and finance around a shared value framework?

# Payers, Policy & System Alignment



How are payer expectations evolving around LAI MOUD, particularly in Medicaid and value-based arrangements?

# Payers, Policy & System Alignment



What should provider organizations be doing now to position themselves as strong partners focused on outcomes rather than utilization alone?

# Avoiding Misuse & Overgeneralization




Where do you see LAI MOUD being misunderstood or misapplied?

# Avoiding Misuse & Overgeneralization



How can organizations avoid treating it as either a silver bullet or a last-resort option, and instead integrate it appropriately into a broader treatment strategy?

# Closing Reflection



If a provider organization could take just one concrete step in the next year to maximize the clinical and financial value of LAI MOUD, where would you advise them to focus, and why?

# Next Webinar: March 31, 2026 11-12 p.m. EST

Treating Fentanyl & High-Potency Synthetic Opioid (HPSO) Use Disorder:  
Evidence-Based MOUD Protocols, Induction Strategies, & Harm Reduction in Real-World Settings

Register Now!

